Publicacions
-
Muñoz JP, Cristina Larrosa Espinosa, Chamorro S, Pérez-Jaume S, Simao M, Sanchez-Sierra N, Varo A, Gorostegui M, Castañeda-Heredia A, Garraus-Oneca M, Lopez-Miralles S and Mora J.
Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes
Cancers . 15(19): . Nº de cites: 6
-
Gomez-Gonzalez S, Llano-Viles J, Garcia-López M, Garrido- García A, Suñol M, Lemos I, Pérez-Jaume S, Salvador-Marcos N, Gene-Olaciregui N, Galán RA, Santa-María López V, Pérez-Somarriba M, Castañeda-Heredia A, Hinojosa J, Winter U, Moreira FB, Lubieniecki F, Vazquez V, Mora J, Cruz-Martínez O, Morales-La Madrid A, Perera A and Lavarino C.
EpiGe: A machine-learning strategy for rapid classification of medulloblastoma using PCR-based methyl-genotyping
iScience . 26(9): 107598-107598. Nº de cites: 1
-
Cristina Larrosa Espinosa, Mora J and Cheung NK.
Global Impact of Monoclonal Antibodies (mAbs) in Children: A Focus on Anti-GD2
Cancers . 15(14): . Nº de cites: 5
-
Reinal I, Ontoria-Oviedo I, Selva M, Casini M, Peiró-Molina E, Fambuena-Santos C, Climent AM, Balaguer J, Cañete A, Mora J, Raya Á and Sepúlveda P.
Modeling Cardiotoxicity in Pediatric Oncology Patients Using Patient-Specific iPSC-Derived Cardiomyocytes Reveals Downregulation of Cardioprotective microRNAs
ANTIOXIDANTS . 12(7): .
-
Aschero MR, Castillo H, Baulenas-Farrés M, Resa-Parés C, Jiménez-Cabaco A, Rodriguez E, Monterrubio C, Pérez-Jaume S, Suñol M, Chantada G, Lavarino C, Mora J and Carcaboso AM.
Prognostic value of xenograft engraftment in patients with metastatic high-risk neuroblastoma
PEDIATRIC BLOOD & CANCER . 70(6): . Nº de cites: 3
-
Xu L, Pierce JL, Sanchez A, Chen KS, Shukla AA, Fustino NJ, Stuart SH, Bagrodia A, Xiao X, Guo L, Krailo MD, Shaikh F, Billmire DF, Pashankar F, Bestrashniy J, Oosterhuis JW, Gillis AJM, Xie Y, Teot L, Mora J, Poynter JN, Rakheja D, Looijenga LHJ, Draper BW, Frazier AL and Amatruda JF.
Integrated genomic analysis reveals aberrations in WNT signaling in germ cell tumors of childhood and adolescence
NATURE COMMUNICATIONS . 14(1): 2636-2636. Nº de cites: 6
-
Varo A, Castañeda-Heredia A, Chamorro S, Muñoz JP, Gorostegui M, Celma MS, Lopez S, Simao M, Pérez-Jaume S and Mora J.
Novel infusion strategy reduces severe adverse events caused by the anti-GD2 monoclonal antibody naxitamab
Frontiers in oncology . 13: 1164949-1164949. Nº de cites: 4
-
Mora J, Castañeda-Heredia A, Gorostegui M, Varo A, Pérez-Jaume S, Simao M, Muñoz JP, Garraus-Oneca M, Cristina Larrosa Espinosa, Salvador-Marcos N, Lavarino C, Krauel L and Mañe S.
Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use-Updated Outcome Report
Cancers . 15(9): . Nº de cites: 6
-
Pascual-Pastó G, Resa-Parés C, Castillo H, Aschero MR, Baulenas-Farrés M, Vilà-Ubach M, Burgeño-Sandoval V, Balaguer-Lluna L, Cuadrado-Vilanova M, Gene-Olaciregui N, Martinez N, Pérez-Jaume S, de Alava, E, Tirado, OM, Lavarino C, Mora J and Carcaboso AM.
Low Bcl-2 is a robust biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma
BIOCHEMICAL PHARMACOLOGY . 208: 115408-115408. Nº de cites: 6
-
Figuerola-Bou E, Rios-Astorch C, Blanco E, Sanchez-Jimenez M, Táboas-Outón P, Fernandez-Isern G, Gomez-Gonzalez S, Muñoz-Aznar O, Castellano P, Pérez-Jaume S, Prada-Varela E, Mateo-Lozano S, Riggi N, Avgustinova A, Lavarino C, Di Croce L, Sánchez-Molina S and Mora J.
KDM6 demethylases mediate EWSR1-FLI1-driven oncogenic transformation in Ewing Sarcoma
Biorxiv . : .